Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2‐positive breast cancer: An open‐label, dose‐escalation, phase I study

Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2‐positive breast cancer: An open‐label, dose‐escalation, phase I study

Abstract Background The introductions of anti‐ human epidermal growth factor receptor‐2 (HER2) agents have significantly improved the treatment outcome of patients with HER2‐positive breast cancer. BAT8001 is a novel antibody‐drug conjugate targeting human epidermal growth factor receptor‐2 (HER2)‐e...

Full description

Bibliographic Details
Main Authors: Ruoxi Hong, Wen Xia, Liye Wang, Kaping Lee, Qianyi Lu, Kuikui Jiang, Shengfeng Li, Jinquan Yu, Jin Wei, Weijia Tang, Danyang Zhou, Xin An, Jiajia Huang, Cong Xue, Xiwen Bi, Yanxia Shi, Zhongyu Yuan, Fei Xu, Shusen Wang
Format: Article
Language:English
Published: Wiley 2021-02-01
Series:Cancer Communications
Subjects:
BAT8001
antibody‐drug conjugate
HER2‐postive
breast cancer
dose escalation
maximum tolerated dose
Online Access:https://doi.org/10.1002/cac2.12135

Internet

https://doi.org/10.1002/cac2.12135

Similar Items